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Helicobacter pylori and Campylobacter jejuni colonize the stomach and intestinal mucus, respectively. Using a combination of
mucus-secreting cells, purifiedmucins, and a novel mucin microarray platform, we examined the interactions of these two or-
ganisms with mucus and mucins.H. pylori and C. jejuni bound to distinctly different mucins. C. jejuni displayed a striking tro-
pism for chicken gastrointestinal mucins compared to mucins from other animals and preferentially boundmucins from spe-
cific avian intestinal sites (in order of descending preference: the large intestine, proximal small intestine, and cecum).H. pylori
bound to a number of animal mucins, including porcine stomach mucin, but with less avidity than that of C. jejuni for chicken
mucin. The strengths of interaction of various wild-type strains ofH. pyloriwith different animal mucins were comparable, even
though they did not all express the same adhesins. The production of mucus by HT29-MTX-E12 cells promoted higher levels of
infection by C. jejuni andH. pylori than those for the non-mucus-producing parental cell lines. Both C. jejuni andH. pylori
bound to HT29-MTX-E12mucus, and while both organisms bound to glycosylated epitopes in the glycolipid fraction of the mu-
cus, only C. jejuni bound to purified mucin. This study highlights the role of mucus in promoting bacterial infection and empha-
sizes the potential for even closely related bacteria to interact with mucus in different ways to establish successful infections.
The identification of two layers of mucus in the gastrointestinaltract (1, 2) and the profiling of bacterial species that inhabit
different mucosal sites throughout the body (3–5) have evoked
intense interest in how bacteria colonize mucosal surfaces. Mucus
is part of the innate host defense systems of humans and animals.
An important function is to create a physical barrier that limits
infection by pathogenic organisms (6). Many organisms have de-
veloped strategies to overcome this barrier, and most infections
occur at mucosal surfaces. Understanding the molecular mecha-
nisms that pathogenic organisms use to colonize the mucus layer
is clearly important, since such knowledge may suggest novel ap-
proaches for the prevention of colonization by pathogens.
Helicobacter pylori and Campylobacter jejuni are two closely
related but distinct mucosal pathogens that have adapted to infect
different niches in the mucus layer of the human gastrointestinal
tract. H. pylori infection, one of the most common infections of
humans, causes gastritis, duodenal ulceration, and an increased
risk of developing gastric cancer (7). This organism colonizes the
gastric mucosae of humans and some other primates but does not
colonize other hosts naturally. H. pylori predominantly colonizes
the supramucosal gel of the stomach (8). The mucus gel acts as an
infectious reservoir providing a steady supply of organisms that
can interactwith the underlying epitheliumand cause disease. The
binding of H. pylori to gastric mucin has been shown to be medi-
ated via the bacterial adhesin BabA (9), which binds to the Lewisb
blood group antigen (9). H. pylori also binds to sialyl-Lewisx via
the SabA outer membrane protein (OMP) (10).H. pylori exhibits
high genomic plasticity due to high rates of mutation and homol-
ogous recombination (11, 12). Individual strains have been shown
to modulate both their own adhesin expression and host glycan
expression following infection (13, 14). The dynamic modulation
of H. pylori attachment is thought to confer an advantage on the
bacterium, enabling it to respond rapidly to changes in its envi-
ronment.
C. jejuni is a highly motile intestinal pathogen and the leading
cause of bacterial gastroenteritis in humans in the developed
world. This organism colonizes chickens and other poultry natu-
rally, without causing pathology, and chickens are an important
reservoir of infection for humans. The ability of the organism to
colonize intestinal mucus is thought to be an important virulence
factor, and exposure of C. jejuni to the human intestinal mucin
Muc2 has been shown to have an effect on virulence gene expres-
sion (15). Glycans present on chicken intestinal mucin have been
shown to inhibit C. jejuni invasion of HCT-8 cells (16, 17). C.
jejuni can interact with blood group antigens present in human
milk, and binding to epithelial cells is inhibited by human milk-
derived fucosyl oligosaccharides (18). Recent work has profiled
the binding ofC. jejuni to glycans at 42°C, the body temperature of
avian species, and 37°C, and differences have been noted (19).
However, very little information exists on the carbohydrate-lectin
pairs involved in mediating infections by C. jejuni.
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New tools that enable us to study the interaction of bacteria
with mucin oligosaccharides have become available recently.
These include cell lines that produce adherent mucus layers (20,
21) and novel mucin microarrays that contain natural mucins
from different animal species (22). This study aimed to examine
the interactions of both H. pylori and C. jejuni with mucus and
mucins by harnessing these novel techniques. Our results show
that these two closely related bacteria interact with mucus in very
different ways, and they highlight the role of mucus in promoting
bacterial infection. This study also emphasizes that glycans pres-
ent on host mucins and other glycosylated structures in mucus
likely play a key role in the specific species and tissue tropism
displayed by bacteria. These data underline the importance of elu-
cidating how bacteria interact with mucus in order to overcome
this important protective barrier and establish successful infec-
tions.
MATERIALS AND METHODS
Bacterial strains, routine maintenance, and culture. The strains of C.
jejuni used in this study included the well-characterized strains 81-176
(23, 24) and 11168 (25), two chicken isolates, CC18 andCC19 (a gift from
Seamus Fanning, University College Dublin [UCD], Dublin, Ireland),
and two human isolates, H1 and H3 (a gift from Margaret Byrne, Our
Lady’s Children’s Hospital, Dublin, Ireland). C. jejuni strains were rou-
tinely cultured at 37°C on Mueller-Hinton agar (Oxoid) under mi-
croaerophilic conditions generated using CampyGen gas packs (Oxoid).
The strains of H. pylori used in this study included the sequenced
strains 26695 (26), J99 (27), and G27 (28), as well as a babA knockout
mutant of G27, strain G27babA (a gift from Steffen Backert). H. pylori
was routinely cultured at 37°C on Columbia blood agar base (Oxoid)
containing 7% (vol/vol) defibrinated horse blood under microaerophilic
conditions generated using CampyGen gas packs (Oxoid). Strain
G27babA was cultured on plates containing 10 g/ml of kanamycin.
Cell culture. The LS174T (29) and HT29 (30) human colonic carci-
noma cell lines, methotrexate (MTX)-adapted HT29 cells (HT29-MTX)
(31), and a mucus-secreting subclone, the HT29-MTX-E12 cell line (32),
were used. TheHT29-MTX-E12 cell line is a subclone ofHT29-MTX cells
that expresses the gastric mucin MUC5AC (21), selected on the basis of
tight-junction formation and the production of an adherent mucus layer
(32). HT29 cells were maintained in McCoy’s medium (Lonza) supple-
mented with 10% (vol/vol) fetal bovine serum (FBS), 1% (vol/vol) non-
essential amino acids (Sigma), 2mML-GlutaMAX (Invitrogen), 100U/ml
penicillin (Sigma), 100 g/ml streptomycin (Sigma), and 125 g/ml am-
photericin B (Sigma). LS174T, HT29-MTX, and HT29-MTX-E12 cells
were maintained in Dulbecco’s modified Eagle medium (DMEM; Lonza)
supplemented with 10% (vol/vol) FBS, 1% (vol/vol) nonessential amino
acids (Sigma), 2 mM L-GlutaMAX (Invitrogen), 100 U/ml penicillin
(Sigma), 100 g/ml streptomycin (Sigma), and 125 g/ml amphotericin
B (Sigma).
Mucus harvesting and mucin purification. HT29-MTX-E12 cells
were grown for 21 days onTranswell filters. Themucus layer was removed
from the cells by treatment withN-acetyl cysteine, as described previously
(16, 20). LS174T cells were cultured as described above, and once they
were 60 to 80% confluent, the supernatant containing secretedmucuswas
collected. Mucus samples from either the reproductive tracts or digestive
tracts of cows, chickens, deer, horses, mice, sheep, pigs, and rats were
obtained either postmortem from healthy animals killed at commercial
abattoirs or after humane euthanasia by an intravenous barbiturate over-
dose. Generally, mucosal surfaces were scraped with a scalpel blade to
harvest secreted mucus and epithelial cells. These experimental proce-
dureswere licensed by theDepartment ofHealth andChildren, Ireland, in
accordance with the Cruelty to Animals Act (Ireland, 1897) and European
Community Directive 86/609/EC and were sanctioned by the Animals
Research Ethics Committee, University College Dublin, Dublin, Ireland.
Mucins were isolated from the collected mucus and were purified as de-
scribed previously (16, 22). In brief,mucuswas solubilizedwith guanidine
hydrochloride (final concentration, 4 M). Samples were reduced with
dithiothreitol (DTT) (Sigma-Aldrich) at a final concentration of 0.01 M
for 5 h at 37°C and were alkylated with iodoacetamide (0.025M) (Sigma-
Aldrich). Mucin was purified using CsCl density gradient separation fol-
lowed by size exclusion chromatography (16, 22).Non-mucin-containing
fractions from the CsCl gradient were retained for subsequent analysis.
Interrogation of NGC and natural mucin microarrays for bacterial
binding. Purified animal mucins and mucins from HT29-MTX-E12 and
LS174T cells were printed onto microarray slides as described previously
(22). Neoglycoconjugate (NGC) arrays were designed and printed as de-
scribed previously (33). For incubations at 37°C, C. jejuni and H. pylori
were cultured on agar as described above, harvested, and resuspended in
Mueller-Hinton broth or in brain heart infusion (BHI) broth supple-
mented with 10% FBS, respectively, to an optical density at 600 nm
(OD600) of 0.2. Cultures were incubated for 4 h, at which time bacteria
were harvested, washed twice in phosphate-buffered saline (PBS), and
resuspended in PBS to an OD600 of 1.0.
To assess the effect of increased temperature on the binding of C.
jejuni, bacteria were grown in Mueller-Hinton broth for 24 h at 37°C or
42°C prior to incubation with the array. Following incubation with Syto
82 (Invitrogen) for 1 h at 37°C or 42°C, bacteria were washed 7 times in
low-salt Tris-buffered saline (TBS) (22) to remove excess staining and
were resuspended to anOD600 of 1.0 in low-salt TBSwith 0.05%Tween 20
(TBS-T). The microarrays were incubated with fluorescently labeled bac-
teria using an 8-well gasket slide and incubation cassette system (Agilent
Technologies) at 37°C or 42°C with gentle rotation in the dark. The slides
were washed 3 times with low-salt TBS-T and once in TBS. The microar-
rays were dried by centrifugation and were scanned immediately.
Imaging, data extraction, and analysis. Microarray slides were im-
aged in a GenePix 4000b microarray scanner (532-nm laser, 100% laser
power, 70% photomultiplier tube [PMT] setting, tetramethyl rhodamine
isocyanate [TRITC] emission filter) (Molecular Devices). Data from the
resultant image files were extracted using GenePix Pro, version 5.1, and
were exported as text to Excel, where all data analysis was performed.
Local backgroundwas subtracted, and background-correctedmedian fea-
ture intensity was used for each feature intensity value. For statistical use,
the median of six replicate spots per subarray was treated as a single data
point. Data were normalized to the mean for three replicate microarray
slides.
Subcellular fractionationofH.pylori and characterizationofmucin
binding. Bacterial outer membrane proteins from H. pylori were lysed
and isolated using sodium lauryl sarcosine as described previously (34).
Briefly, H. pylori was harvested from blood agar plates, washed in sterile
PBS, harvested by centrifugation at 12,000  g for 20 min at 4°C, and
frozen at 20°C. The pellet was thawed in 20 mM Tris buffer, pH 7.5,
containing protease inhibitor cocktail tablets (Roche). Following 6
rounds of pulse sonication, DNase (0.1 mg/ml) and RNase (0.5 mg/ml)
were added to the sonicated material, which was then incubated for 30
min at room temperature (RT). Unbroken cells were removed (2,000 g,
20 min, 4°C), and the membranes were isolated by centrifugation of the
supernatant at 40,000  g for 30 min at 4°C. The resulting pellet was
resuspended in 20mMTris buffer, pH 7.5, containing 0.2% sodium lauryl
sarcosine and was incubated at RT for 30 min. The outer membrane
fractionwas pelleted by centrifugation at 40,000 g for 30min at 4°C and
was washed 3 times in ice-cold distilled water (dH2O).
Fractions were separated by electrophoresis on 10% polyacrylamide
minigels and were transferred to polyvinylidene difluoride (PVDF)mem-
branes overnight in a wet blotter (Bio-Rad, Hercules, CA) at 10 V. Mem-
branes were blocked in 5% gelatin for 2 h at 37°C. Purified porcine
stomach mucin (13) was biotinylated by using the EZ-Link sulfo-N-hy-
droxysuccinimide (NHS) biotinylation kit (Pierce) according to theman-
ufacturer’s instructions. Blocked membranes were incubated with 0.25
mg/ml biotinylated mucin for 4 h at RT. Membranes were washed for 1 h
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with TBS-Tween (0.05% [vol/vol]) and were then incubated with strepta-
vidin-peroxidase (1:50,000) (Sigma) for 1 h at RT. Membranes were
washed overnight in TBS-Tween (0.05%), and bands were detected using
enhanced chemiluminescence.
Infection assays. Cells were seeded on Transwell filters (diameter, 12
mm; pore size, 0.4 m; Millipore) at a density of 1  105 cells/filter and
were grown for 21 days. Cells were fed every second day andwere grown in
antibiotic-free medium for 24 h prior to infection.
To determine the role of mucus in colonization, bacterial strains were
grown under microaerophilic conditions, and C. jejuni was prepared for
infection of the cells as described previously (20). Briefly, C. jejuni strains
were grown for 24 h on Mueller-Hinton agar plates and were then trans-
ferred to a biphasic medium consisting of Mueller-Hinton agar and
DMEM, supplemented with 2% FBS without antibiotics, for a further 21
to 24 h. Bacteria were harvested from the biphasic medium, washed once
inDMEM, and then diluted to anOD600 of 0.2.H. pylori grown for 48 h on
Columbia blood agar plates was harvested into BHI broth at pH 5.0, and
the OD600 was adjusted to 0.4.
The medium in the lower chamber of the Transwell was replaced with
1.5 ml of sterile antibiotic-free McCoy’s 5A medium or DMEM, each
supplemented with 10% (vol/vol) FBS. For C. jejuni infections, 150 l of
aC. jejuni suspension at anOD600 of 0.2 was added to the upper chamber.
H. pylori cannot survive in DMEM (35), so 100 l of BHI broth at pH 5.0
and 50l of theH. pylori suspension (OD600, 0.4) were added to the upper
chamber. The number of organisms added to cells was approximately 1
108 CFU/ml, which corresponded to a multiplicity of infection (MOI) of
50 organisms per cell.
Infected cell cultures were incubated under microaerophilic condi-
tions generated using CampyGen gas packs (Oxoid) at 37°C for 24 h.
Following incubation, infected cells were washed with sterile PBS and
were then harvested using trypsin-EDTA as described previously (36).
Serial dilutions of the trypsinized cells were plated out in triplicate onto
Mueller-Hinton agar plates or Columbia blood agar plates for assessment
of C. jejuni or H. pylori organisms associated with the cells and were
incubated under microaerophilic conditions at 37°C. Colonies were enu-
merated after 4 to 5 days of incubation.
To determine the effect of temperature on infection and invasion byC.
jejuni, strains were grown for 24 h at 37°C onMueller-Hinton agar plates
and were then transferred to Mueller-Hinton broth for a further 24 h at
either 37°C or 42°C. Bacteria were harvested from the broth, washed once
inDMEM, and then diluted to anOD600 of 0.2. Cell cultures were infected
as described above and were incubated for 4 h at 37°C or 42°C. Following
the incubation period, one set of wells was used to determine total asso-
ciation as described above. The second set of wells was washed once in
DMEM and was then incubated with 400 g/ml gentamicin sulfate (Sig-
ma-Aldrich) in DMEM for 2 h to kill extracellular bacteria. Cells were
then washed once in PBS and were lysed with 0.1% Triton X-100 in PBS.
Serial dilutions of the cell lysate were plated out in triplicate ontoMueller-
Hinton agar plates for assessment of internalized C. jejuni organisms and
were incubated under microaerophilic conditions at 37°C. Colonies were
enumerated after 3 to 4 days of incubation.
Probing of mucus and mucin of E12 cells with C. jejuni and H.
pylori. Crude mucus or 10 g of purified mucin from E12 cells was im-
mobilized onto a PVDFmembranewith a pore size of 0.2m(Millipore).
Membranes were washed in PBS and were then blocked overnight in TBS
containing 5% skimmilk.C. jejuni orH. pyloriwas cultured on agar plates
as described above, harvested in PBS, washed twice, and resuspended in
TBS to a finalOD600 of 0.4. A suspension of eitherC. jejuni orH. pyloriwas
then overlaid onto the membrane and was incubated at 37°C for 1 h. The
overlays were washed three times at room temperature for 10 min on a
rotary shaker in TBS containing 0.05%Tween 20. Binding ofC. jejuniwas
detected using a 1:5,000 dilution of a rabbit anti-C. jejuni antiserum (37)
and a horseradish peroxidase (HRP)-conjugated anti-rabbit secondary
antibody (Santa Cruz). H. pylori binding was detected using an anti-H.
pylori polyclonal antibody (Dako) and an HRP -conjugated anti-rabbit
secondary antibody (Santa Cruz). Reactive slots were detected using en-
hanced chemiluminescence.
O-glycan analysis of purified mucin from HT29-MTX-E12 cells.
Mucinswere purified as described above andwere freeze-dried. Then 28%
NH3·H2O saturated with (NH4)2CO3 was added to a final mucin concen-
tration of 1mg/ml. Themixture was incubated at 65°C for 16 h in order to
release the O-glycans. For glycan enrichment after release, HypercarbMi-
croSPE tips were conditioned twice with 200 l of methanol, twice with
200 l of Milli-Q water, and finally twice with 200 l of 10 mM ammo-
nium carbonate before the sample (in an aqueous solution; final volume,
200 l) was applied. After the sample had passed through the tip, the
chromatographic bed was washed 5 times with 200 l of Milli-Q water in
order to remove excess release reagents. The retained glycans were eluted
from the Hypercarb bed 5 times, using 100 l of 10 mM ammonium
carbonate solution in 80% (vol/vol) acetonitrile each time, and the eluates
from all these elution steps were collected in a singlemicrocentrifuge tube
and were dried down in a SpeedVac concentrator. Once dry, the samples
were treated with formic acid to convert them back to the aldose form and
were derivatized with 2-aminobenzamide (2-AB) as described previously
(38). 2-AB-labeled glycanswere analyzed by hydrophilic interaction chro-
matography (HILIC) (38, 39), and the glucose unit (GU) values were
compared to those in the O-glycan database (http://glycobase.nibrt.ie
/glycobase/show_nibrt.action). Further confirmation of the structures
proposed was obtained by exoglycosidase digestion.
Exoglycosidase digestion. Arrays of exoglycosidases were used in
combination with HILIC–high-performance liquid chromatography
(HPLC) to determine the sequence, monosaccharide type, and linkage of
sugar residues. Exoglycosidase sequencing was performed on 2-AB-la-
beled O-glycans in 10 l of a solution containing enzymes at standard
concentrations in the manufacturer’s recommended buffers for 16 h at
37°C. The enzymes used were as follows:Arthrobacter ureafaciens sialidase
(ABS) (EC 3.2.1.18), 1 to 2 U/ml; Streptococcus pneumoniae sialidase re-
combinant in Escherichia coli (NAN1) (EC 3.2.1.18), 1 U/ml; bovine kid-
ney-fucosidase (BKF) (EC 3.2.1.51), 1 U/ml; almondmeal-fucosidase
(AMF) (EC 3.2.1.111), 3mU/ml; bovine testis-galactosidase (BTG) (EC
3.2.1.23), 2 U/ml; Streptococcus pneumoniae -galactosidase (SPG) (EC
3.2.1.23), 80 mU/ml; and -N-acetylglucosaminidase cloned from S.
pneumoniae, expressed in Escherichia coli (GUH) (EC 3.2.1.30), 10 mU/
ml. After digestion, samples were separated from the exoglycosidases be-
foreHPLC analysis by centrifugation in aNanosep 10KOmegamicrocen-
trifuge filter (Pall, VWR).
WAXchromatography.Neutral and acidic oligosaccharideswere sep-
arated byweak anion-exchange (WAX)-HPLCusing aVydac 301VHP575
column (7.5 by 50mm; Anachem) on a 2695 Alliance Separationsmodule
with a 474 fluorescence detector set (excitation and emissionwavelengths,
330 and 420 nm, respectively) (Waters). Solvent A consisted of 0.1 M
ammonium acetate buffer, pH 7.0, in 20% (vol/vol) acetonitrile, and sol-
vent B was 20% acetonitrile. Gradient conditions were as follows: a linear
gradient of 0 to 5% solvent A over 12 min at a flow rate of 1 ml/min,
followed by 5 to 21% solvent A over 13 min, 21 to 50% solvent A over 25
min, 80 to 100% solvent A over 5 min, and 5 min at 100% solvent A.
Samples were injected in water, and a fetuin N-glycan standard was used
for calibration.
Immunofluorescent staining of HT29-MTX-E12 cells.HT29-MTX-
E12 cells growing on Transwell filters were washed with PBS, removed
from their plastic supports, and sandwiched between two thin pieces of
chicken liver prior to mounting in optimal cutting temperature (OCT)
medium (BDH) as described previously, (40). Sections (20 m) were cut
using a cryostat, collected on polylysine-coated microscope slides, al-
lowed to air dry, and then either used immediately or stored at 20°C
until use.
Sections were fixed on slides with 2% formalin for 10 min, permeab-
ilized with 0.2% (wt/vol) saponin (Sigma) in PBS for 10 min, blocked for
1 h in 1% (wt/vol) bovine serum albumin (BSA; Sigma) and 10% (vol/vol)
serum in PBS, and probed with an anti-Lewisb antibody (SPM194; Santa
Naughton et al.
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Cruz) or anti-sialyl-Lewisx (Molecular Probes) and a secondary anti-
mouse antibody conjugated to Alexa Fluor 488 (Invitrogen). DAPI (4=,6-
diamidino-2-phenylindole) (Invitrogen)was used to counterstain the nu-
clei. Coverslips were mounted on the slides using Fluorescent Mounting
Medium (Dako), and the sections were examined with a fluorescence
microscope.
Detection of Lewisb blood group antigen inHT29-MTX-E12mucus
fractions. Following CsCl gradient fractionation of E12 mucus, non-mu-
cin-containing fractions were slot blotted onto a PVDF membrane (Mil-
lipore).Membranes were washed in PBS andwere then blocked overnight
in TBS containing 5% skim milk. Lewisb was detected in the fractions by
using an antibody against Lewisb blood group antigen (SPM194; Santa
Cruz) and a secondary anti-mouse antibody conjugated to HRP. Reactive
slots were detected by enhanced chemiluminescence.
Glycolipid isolation and characterization and C. jejuni and H. py-
lori binding.Glycolipids were isolated frommucus bymultiple rounds of
chloroform-methanol extraction. Mucus was harvested as described
above, and organic extraction of mucus was carried out according to the
method of Muindi et al. (41). Briefly, lipids were obtained by successive
extractions with chloroform-methanol (1:1 followed by 1:2 [vol/vol]) and
a final extraction with chloroform-methanol-water (4.8:3.5:1). The re-
sulting glycolipids were separated by thin-layer chromatography (TLC)
using chloroform-methanol-0.25% KCl (5:4:1) as a solvent system with
silica TLC plates (Fisher). Glycolipid bands were visualized with a 0.1%
orcinol-H2SO4 stain and were charred using a heat gun. TLC plates con-
taining separated glycolipids were treated with 0.1% polyisobutylmethac-
rylate in acetone, dried, and probed with antibodies against Lewisb and
sialyl-Lewisx. The TLC plates were also overlaid with eitherH. pylori orC.
jejuni organisms and were probed with antibodies raised againstH. pylori
or C. jejuni. TLC plates were probed with alkaline phosphatase-conju-
gated secondary antibodies (Santa Cruz), and antigen-antibody com-
plexes were detected using the colorimetric substrate BCIP (5-bromo-4-
chloro-3-indolylphosphate)-NBT (nitroblue tetrazolium) (Sigma).
Statistical analysis. Infection assayswere carried out on three separate
occasions in triplicate. Microarray interrogation was conducted in dupli-
cate permicroarray slide, and data were normalized to themeans for three
replicate microarray slides. Graphs were drawn using GraphPad Prism.
Results are presented as means standard deviations (indicated by error
bars) for replicate experiments. The Student t test was used to estimate
statistical significance; a P value of0.01 was considered significant.
RESULTS
The interaction of C. jejuni and H. pylori with purified native
mucins from different animal species reveals species tropism.
We investigated the binding ofH. pylori andC. jejuni to a panel of
natural mucins from different animals printed on a microarray
that enables the generation of quantitative binding data. C. jejuni
and H. pylori bound to distinctly different mucins, and each
showed tropism for mucins from specific sites among different
animal species.
C. jejuni displayed a tropism for chicken mucin in preference
to mucins from other animals (Table 1). All 6 isolates of C. jejuni
(81-176, 11168, 2 chicken isolates, and 2 human clinical isolates)
showed a clear tropism formucin fromchickens, with the strength
of the interaction dependent on the site of origin of the mucin (in
descending order of interaction strength: the large intestine, prox-
imal small intestine, and cecum) (Fig. 1). The binding of C. jejuni
to chickenmucinwas not influenced by growth at human or avian
body temperature (Fig. 1). C. jejuni also bound to mucins from
other animals, including equine, porcine, ovine, and bovine mu-
cins. However, the strength of the interactions with these mucins
was not as great as that seen with chicken large-intestine mucin
(Table 1). The patterns of binding were consistent across different
C. jejuni isolates andwere comparable at 37°C and 42°C (see Table
S1 in the supplemental material).
H. pylori bound to a distinctly different subset of mucins
than that seen with C. jejuni (Table 1). Three wild-type strains
of H. pylori and a BabA knockout strain were used to probe the
array. The wild-type organisms all displayed appreciable bind-
ing to porcine stomach mucin, although the intensity of the
interaction was substantially less than the intensity of the bind-
ing of C. jejuni to chicken large-intestine mucin. H. pylori also
bound to other mucins, including rat gastric and duodenal
mucins (Fig. 2; Table 1). The wild-type strains all displayed
similar binding profiles. However, strain G27babA exhibited
reduced binding to a number of mucins, including those of
porcine and rat origins, relative to binding by the parental
TABLE 1 Binding of C. jejuni strain 81-176 and H. pylori strain 26695 to
natural mucins on a mucin microarray
Mucin sourcea
Level of bindingb of:
C. jejuni
81-176
H. pylori
26695
Abomasum (B) 2,780 2,158
Cervicovaginal (B) 472 521
Cervix (B) 497 505
Duodenum (B) 795 289
Spiral colon (B) 1,131 288
Trachea (B) 533 261
Endometrium (B) 554 177
Cecum (C) 3,884 387
Proximal small intestine (C) 8,775 625
Large intestine (C) 14,344 571
Abomasum (D) 2,021 2,261
Duodenum (D) 121 487
Jejunum (D) 144 653
Spiral ascending colon (D) 816 172
HT29-MTX-E12 cells 3,192 1,108
Dorsal ascending colon (E) 925 2,036
Duodenum (E) 1,183 1,794
Left ventral ascending colon (E) 1,883 965
Right ventral ascending colon (E) 3,255 1,786
Jejunum (E) 1,891 3,064
Stomach (E) 218 493
Trachea (E) 313 404
LS174T cells 4,298 14,409
Cecum (M) 483 1,157
Large intestine (M) 1,001 1,907
Small Intestine (M) 202 353
Stomach (M) 694 1,074
Abomasum antrum (O) 343 1,126
Descending colon (O) 866 1,826
Duodenum (O) 1,576 1,124
Ileum (O) 724 778
Jejunum (O) 652 1,393
Spiral colon (O) 2,654 7,759
Cecum (P) 4,221 6,038
Descending colon (P) 1,423 256
Jejunum (P) 1,055 2,903
Spiral colon (P) 1,211 3,372
Stomach (P) 2,522 7,915
Cecum (R) 1,031 4,302
Colon (R) 1,011 482
Duodenum (R) 902 5,827
Ileum (R) 501 1,446
Stomach (R) 1,101 4,688
a B, bovine; C, chicken; D, deer; E, equine; M, mouse; O, ovine; P, porcine; R, rat.
b Expressed as the mean fluorescence intensity (in relative fluorescence units) from
duplicate individual microarrays across 3 different array slides. The binding
temperature was 37°C.
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strain (Fig. 2), suggesting that the BabA outer membrane pro-
tein (OMP) was playing a role in mediating the interaction
between H. pylori G27 and a number of mucins.
Role ofOMPs inmediating thebindingofH.pylori tomucin.
In order to investigate the potential contribution of OMPs tomu-
cin binding, we probed OMPs from each of the H. pylori strains
with biotinylated porcine stomach mucin. Mucin bound specifi-
cally to an 80-kDa OMP in strains G27 and J99 but not in
G27babA or 26695 (Fig. 3A). Direct binding of these H. pylori
isolates to Lewis blood group antigen structures on an NGC array
confirmed that strain 26695 demonstrated lower levels of binding
to both Lewisb and sialyl-Lewisx structures than strains J99 and
G27 (Fig. 3B). The results suggest that BabA, when expressed, can
mediate the binding ofH. pylori to porcine stomachmucin. How-
ever, in the case of strain 26695, for which no OMP could be
detected to mediate binding, this interaction may be mediated by
a non-protein-based bacterial adhesin.
Mucus promotes infection by both H. pylori and C. jejuni.
These experiments point to a fundamental role of mucus in C.
jejuni and H. pylori infection. In order to explore this further, we
examined the interactions of the organisms withHT29-MTX-E12
cells, which harbor an adherent mucus layer, and compared col-
onization efficiencies with parental HT29-MTX (mucus-secret-
ing) and HT29 (non-mucus-secreting) cells. To determine the
effects of secreted mucins and an adherent mucus layer on the
interactions between host cells and C. jejuni or H. pylori, a com-
parison wasmade of the colonization of 3 cell lines (HT29, HT29-
MTX, and HT29-MTX-E12) with the two organisms. All coloni-
zation studies were carried out on cells grown on Transwell filters
for 21 days, because at this time the HT29-MTX-E12 cells had
produced a mature adherent mucus layer and had formed tight
junctions, while HT29-MTX cells were also fully differentiated
and secreted mucins (21). Higher numbers of H. pylori and C.
jejuni bacteria colonized the HT29-MTX-E12 cells than the
HT29-MTX or HT29 cells (Fig. 4). Strikingly, H. pylori did not
colonize the non-mucus-secreting HT29 cells. In addition, while
the organism could colonize the mucin-secreting HT29-MTX
cells (6.32  102 CFU/ml), the number of organisms recovered
from the HT29-MTX-E12 cells, with an adherent mucus layer,
was markedly higher (2.4 107 CFU/ml) (P 0.01) (Fig. 4). The
numbers of C. jejuni organisms recovered from the HT29 and
HT29-MTX cells (9 106 CFU/ml and 1.5 107 CFU/ml, respec-
FIG 1 Interaction of C. jejuniwith chickenmucins printed on a mucin microarray slide. Microarrays containing purified chickenmucins from different sites in
the intestinal tract were probed with 6 strains of fluorescently labeled C. jejuni organisms. For incubations at 37°C, C. jejuni strains were cultured on agar as
described in Materials and Methods, harvested, and resuspended in Mueller-Hinton broth supplemented with 10% FBS. Cultures were grown for 4 h, at which
time bacteria were harvested, washed, and resuspended in PBS to an OD600 of 1.0. To assess the effect of temperature on the binding of C. jejuni, bacteria were
grown inMueller-Hinton broth for 24 h at 37°Cor 42°C. Labeling andmicroarray interrogationswere carried out at 37°Cor 42°C. The histogram shows themean
fluorescence intensities from duplicate subarrays on three replicate microarray slides; values for each subarray are medians for six feature replicates. Error bars
indicate the standard deviations of the means for three microarray slides. RFU, relative fluorescence units.
FIG 2 Interaction of H. pylori with porcine and rat mucins. Mucin microar-
rays were probed with fluorescently labeled H. pylori organisms. Three wild-
type strains and strain G27babA were used. G27babA does not express the
BabA outer membrane protein, which mediates binding to the Lewisb blood
group antigen. H. pylori was cultured on agar as described in Materials and
Methods, harvested, and resuspended in brain heart infusion broth supple-
mented with 10% FBS. Cultures were incubated at 37°C for 4 h, at which time
bacteria were harvested, washed, and resuspended in PBS to an OD600 of 1.0.
Strain G27babAwas cultured in the presence of 10g/ml of kanamycin. The
histogram shows the mean fluorescence intensities from duplicate subarrays
on three replicate microarray slides; values for each subarray are medians for
six feature replicates. Error bars indicate the standard deviations of the means
for three microarray slides.
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tively) were also higher than the numbers of H. pylori organisms
recovered from these cells. Levels of colonization of HT29 and
HT29-MTX-E12 cells were comparable at 42°C and 37°C, an in-
dication that the different body temperatures of humans and
chickens do not influence mucus interaction (see Fig. S1 in the
supplemental material).
Binding of C. jejuni andH. pylori to HT29-MTX-E12mucus
and mucin. In light of the distinctly different mucin-binding sig-
natures ofH. pylori and C. jejuni, we explored further their inter-
actions with purified mucus and mucin from HT29-MTX-E12
cells. An antibody was used to detect bacteria on either mucus or
purified mucin from HT29-MTX-E12 cells immobilized on a
PVDF membrane. C. jejuni was found to bind to both the mucus
and mucin fractions. In contrast,H. pylori bound directly only to
mucus; no appreciable binding to mucin was detected (Fig. 5A).
Binding could be abolished by sodium metaperiodate treatment
of the mucus or mucin (Fig. 5B), indicating that the organisms
were adhering to glycan epitopes. Probing of HT29-MTX-E12
mucin printed on microarray slides also demonstrated markedly
lower levels of binding by H. pylori than by C. jejuni (Fig. 5C).
The observation that H. pylori bound poorly to HT29-MTX-
FIG 3 Role of OMPs in mediating the binding ofH. pylori to mucins. (A) Detection ofH. pylori surface adhesins involved in mucin binding. Outer membrane
protein fractions ofH. pyloriwere prepared andwere probedwith biotinylated porcine stomachmucin. A protein of	80 kDa, corresponding to the expected size
of the surface adhesin BabA, was detected in strains J99 and G27 but was absent from 26695 and from a babA knockout mutant of G27. (B) Binding ofH. pylori
strains to Lewis blood group antigen structures. Microarrays containing neoglyconjugate Lewis blood group antigen structures were probed with fluorescently
labeled H. pylori organisms. The structures probed were Lewisx-BSA (LexBSA), di-Lewisx-aminophenylethyl-human serum albumin (DiLexHSA), tri-Lewisx-
HSA (TriLexHSA), 3=-sialyl-Lewisx-BSA (SLexBSA), 3-sulfo-Lewisx-BSA (3SuLexBSA), 6-sulfo-Lewisx-BSA (6SuLexBSA), and lacto-N-difucohexaose I-BSA,
(LNDHIBSA), which consists of Lewisb tetrasaccharide and lactose and is used as a Lewisb active structure in immunochemical and functional inhibition studies.
Shown are histograms representing the mean fluorescence intensities from three replicate microarray slides ofH. pylori strains binding to printed neoglycocon-
jugates. The dashed line marks the level of marginal or background binding. Error bars represent the standard deviations of the means for three replicate
microarray slides.
FIG 4 Infection of HT29, HT29-MTX, and HT29-MTX-E12 cells by mucosal
pathogens. TheHT29-MTX subclone E12, with an adherentmucus layer, mu-
cus-secreting HT29-MTX cells, and non-mucus-secreting HT29 cells were
grown for 21 days on Transwell filters and were subsequently infected with C.
jejuni or H. pylori organisms for 24 h. C. jejuni infected all cell lines. The
numbers of C. jejuni organisms colonizing HT29-MTX and HT29-MTX-E12
cells were statistically significantly higher than the number colonizing HT29
cells (P 0.05). In contrast,H. pylori colonized HT29-MTX-E12 cells and, to
a much lesser extent, HT29-MTX cells but not HT29 cells. The data presented
are means standard deviations for 3 replicate experiments (n
 9).
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E12 mucin was surprising given that the adherent mucus layer of
this cell line contains the gastric mucin MUC5AC (21). H. pylori
does not colonize the colon or adhere in vivo to colonic cells.
Therefore, in order to determine whether the lack of binding ofH.
pylori to HT29-MTX-E12mucin was a result of the colonic origin
of themucin, we compared the binding ofH. pylori andC. jejuni to
mucin purified from another colorectal adenocarcinoma cell line,
LS174T. In contrast to the findings with HT29-MTX-E12 mucin,
H. pylori interacted strongly with the LS174T mucin. In fact, C.
jejuni also bound better to LS174Tmucin than to E12mucin (Fig.
5C and D).
O-glycan profile of purified secreted mucin from HT29-
MTX-E12 cells. Bacterial binding to mucins is mediated by in-
teractions between bacterial adhesins and O-glycans on the
mucins. The failure of H. pylori to interact with HT29-MTX-
E12 mucin suggested that the relevant fucosylated O-glycan
structures were not present on mucin originating from these
cells. In order to investigate this finding further, we determined
the O-glycan profile of purified secreted mucin from HT29-
MTX-E12 cells. The structure of O-glycans detected in HT29-
MTX-E12 mucins (Table 2) was not dissimilar to those re-
ported for mucins secreted from related cell lines, such as HT29
(42) and HT29-MTX (43). They comprised mainly core 1- and
core 2-related structures, with a high proportion of truncated
structures (lower GU values) (Fig. 6). Analysis of O-glycans by
WAX chromatography showed that a substantial proportion of
the O-glycans present in mucins secreted from HT29-MTX-
E12 cells were acidic. The same analysis after sialidase digestion
showed no remnant acidic structures, confirming that all the
charged species observed are sialylated glycans (Fig. 7). A no-
ticeable paucity of fucosylated structures was detected, suggest-
ing that a lack of relevant receptors could explain the weak
interaction of H. pylori with E12 purified mucin.
Presence of Lewisb and sialyl Lewisx antigens inHT29-MTX-
E12 cells.Despite the lack of detection of fucosylated structures in
mucin purified from HT29-MTX-E12 cells, staining of the cells
with an antibody against Lewisb clearly demonstrated the presence
of Lewisb blood group antigen in the adherent mucus layer of the
cells. Sialyl-Lewisx staining of the mucus layer was weaker, but
cellular staining for this antigen showed the presence of this struc-
ture on HT29-MTX-E12 cells (Fig. 8).
Interactions ofH. pylori and C. jejuni with non-mucin-con-
taining fractions of E12 mucus. To determine the nonmucin
component(s) of HT29-MTX-E12 mucus that contained Lewisb
blood group antigens, mucus fractions were obtained from a
CsCl gradient and were probed with an antibody against
Lewisb. The first two fractions collected from the top of the
gradient (densities, 1.27 to 1.28 g/ml) reacted with the anti-
Lewisb antibody (Fig. 9A). Cellular glycolipids are known to act
as receptors for the binding of both H. pylori and C. jejuni (14,
44) and have been found in CsCl density gradient fractions in
the range in which we found Lewisb structures (45). Therefore,
we asked whether HT29-MTX-E12 mucus contained glycolip-
ids and, if so, whether these could provide a source of receptors
FIG 5 Interactions ofC. jejuni andH. pyloriwithmucins from themucus-secreting cell lines HT29-MTX-E12 and LS174T. (A)Mucus and purifiedmucin from
HT29-MTX-E12 cells were immobilized on a PVDFmembrane andwere probedwithC. jejuni strain 81-176 orH. pylori strain 26695. BothC. jejuni andH. pylori
bound to immobilized mucus, but only C. jejuni bound directly to purified mucin. (B) Oxidation of the glycan structures by sodiummetaperiodate reduced the
binding of C. jejuni andH. pylori to mucus as well as the interaction of C. jejuniwith purified E12 mucin. (C and D) Interrogation of mucin microarrays with C.
jejuni andH. pylori showed differential binding of both pathogens tomucins from two colonic cell lines, HT29-MTX-E12 (C) and LS174T (D). Histograms show
mean fluorescence intensities from duplicate subarrays on three replicate microarray slides; values for each subarray are medians for six feature replicates. Error
bars are standard deviations of the means for 3 experiments.
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for bacterial binding. Orcinol staining demonstrated the pres-
ence of glycolipids in the organic extract of the mucus sepa-
rated on TLC plates (Fig. 9B). Probing of these glycolipids with
antibodies against both Lewisb and sialyl Lewisx revealed that
both glycans were expressed on the glycolipids (Fig. 9C). Fur-
thermore, overlay assays with H. pylori and C. jejuni revealed
that the organisms could bind to glycolipids isolated from
HT29-MTX-E12 mucus (Fig. 9D). These results highlight the
importance of non-mucin-based glycan interactions in medi-
ating bacterial colonization of mucus.
TABLE 2 Structures of O-glycans released from E-12 mucins, described by HILIC-HPLC and exoglycosidase digestion arrays
Peak no. GUa Structureb Enzymatic digestion(s) (GU)c
1 1.00 Monosaccharides (galactose)
2 1.73 BTG (partial)
3 1.99 ND BTG digest (1.00) (proposed: contaminant lactose)
4 2.23 ABS (1.00), NAN1 (1.00)
5 2.41/2.48/2.54 ND Not digestible by enzymes
6 2.78 GUH, no BTG
7 2.88 GUH (1.73)
8 2.99 ABS (1.73), NAN1 (1.73)
9 3.04 ND Not digestible by enzymes
10 3.24 ABS (1.73), no NAN1
11 3.44 GUH (2.78)
12 3.60 BTG (2.78)
13 3.71 ABS (2.78), NAN1 (2.78)
14 4.24 GUH (3.60), GUH SPG (2.73), GUH BTG (2.73)
15 4.34 ABS (3.58, partial), NAN1 (3.58, partial), ABS BTG (2.78, 3.44), ABS
SPG (2.78), no ABS BTG BKF, no ABS BTG AMF
16 4.4 ABS (1.73), NAN1 (3.24)
17 4.85 GUH (3.58), GUH BTG (2.78)
18 5.03* BTG (4.17), BTG GUH (2.73) (no ABS)
19 5.21* BTG (3.44), BTG GUH (2.78)
20 5.33 ABS (3.58), NAN1 (3.58), BTG (2.78)
21 5.73* BTG (4.85), GUH BTG (2.78)
22 6.33* BTG (4.85), BTG GUH (2.78)
23 6.44* SPG (5.6), BTG (5.6), BTG GUH (2.78)
a Glucose unit (GU) values are averages of triplicates, with a standard deviation of 0.06. Asterisks indicate proposed isomeric structures.
b Structures are represented using the Oxford system for monosaccharides and linkages (Fig. 6, key) (59). ND, not determined.
c The enzymes used were bovine testis -galactosidase (BTG), Arthrobacter ureafaciens sialidase (ABS), Streptococcus pneumoniae sialidase (NAN1), Streptococcus pneumoniae -N-
acetylglucosaminidase (GUH), Streptococcus pneumoniae -galactosidase (SPG), bovine kidney -fucosidase (BKF), and almond meal -fucosidase (AMF).
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DISCUSSION
The gastrointestinal tracts of animals and humans are rich sources
of glycans (46, 47) due to the presence of highly glycosylated mu-
cin molecules in the mucus layer overlying the epithelial cells.
These glycans are often exploited by pathogens to facilitate colo-
nization and disease (46, 48, 49). The expression and glycosylation
of mucins differ depending on a number of factors, including the
species, the location within the body, inflammation, and the pres-
ence of microbes (48, 50, 51). To further the study of bacterial
interactions with complex glycoproteins, a mucin microarray was
developed containing a wide range of natural mucins, including
those from a number of gastrointestinal sites in several animal
species (22). Amajor strength of this technique is that the binding
chemistry of the array slides allows for optimal presentation of the
glycans, therebymaximizing the access of the bacteria to potential
glycan receptors. This enables a quantitative analysis of the inter-
action of bacteria with secreted mucins in a high-throughput for-
mat. Indeed, this improved access to potential binding sites may
explain why we observed a degree of binding ofH. pylori tomucin
from the HT29-MTX-E12 cells on the array that was not detect-
able when mucin immobilized on a PVDF membrane was used.
These natural mucin arrays have been shown previously to be
an effective tool for the profiling ofmucin glycoepitopes (22). Our
analysis indicated thatC. jejuni andH. pylori each interact directly
with a specific subset of mucins. Each pathogen showed a marked
preference formucins from specific sites in certain animal species.
FIG 6 HILIC profile of fluorescently labeled O-glycans released fromHT29-MTX-E12mucins. O-glycans present in this sample were structurally characterized
by HILIC-HPLC and exoglycosidase digestion patterns (see Materials and Methods). O-glycans are represented using the Oxford system for monosaccharides
and linkages (59). A complete description of all structures can be found in Table 2; structures represented in this figure correspond tomajor peaks in the sample,
for which numbers are italicized. Peak 4 is not a natural O-glycan but a peeling product obtained due to the chemical degradation of sialylated structures, most
probably from structure 8 (sialyl-T antigen). The scale of glucose units (GU) is based on the elution of the 2-AB-labeled glucose ladder.
FIG 7 Weak anionic-exchange chromatography of O-glycans released from HT29-MTX-E12 mucins. Separation by charge results in different fractions of
glycans, from neutral (retention time, 4.5 min) to charged (retention time, 11 to 28min) species. The peak at 5.5 min corresponds to excess 2-aminobenzamide.
The retention times of the different O-glycans are compared to those of the fetuin N-glycans, used as standards, where S1 corresponds to monosialylated
N-glycans, and S2 to S4 correspond to di-, tri-, and tetrasialylated N-glycans, respectively. (B) Prevalence of sialylated structures in the acidic fraction of
O-glycans from HT29-MTX-E12 mucins. This panel shows a zoom-in of the chromatogram in panel A (area between 11 and 30 min) before and after A.
ureafaciens sialidase (ABS) digestion.
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While the interaction of H. pylori with gastric mucins has been
extensively studied, little is known about the mechanisms used by
C. jejuni to interact with mucins from either the human or the
chicken gut.C. jejuni ismost commonly identified as a commensal
of chickens, which are the primary source of human infection,
although it has been found in other species, including cattle,
swine, and sheep (52, 53). However, despite the importance of C.
jejuni colonization of chickens in the transmission of the organism
to humans, there are no studies examining directly the interaction
of C. jejuni with chicken mucins. C. jejuni showed a marked tro-
pism for mucin obtained from chicken intestine. In addition to
this species preference, C. jejuni also showed a preference for mu-
cin from specific sites in the chicken gut (in descending order of
preference: the large intestine, proximal small intestine, and ce-
cum). While a previous study demonstrated an interaction be-
tweenC. jejuni lipopolysaccharide (LPS) and rabbit intestinalmu-
cus (54), this is the first study to report this tropism ofC. jejuni for
chickenmucin. In light of the current interest in bacteria and how
they interact withmucosal surfaces (3–5), our results highlight the
importance of selecting an appropriate species for the collection of
mucus for such studies. The finding that the binding ofC. jejuni to
chicken mucin is influenced by the anatomical location from
which the mucus was sourced echoes the results of our previous
studies showing a gradient of inhibition of C. jejuni invasiveness
by chicken mucin, with large intestinal mucus and mucin having
the most profound effect (16, 17). Coupled with recent data sug-
gesting differences in the presence or accessibility of glycans
and/or differing proportions of sulfated glycans in different parts
of the chicken intestine (22), these data point to the fundamental
role of mucin glycosylation in dictating C. jejuni tropism and life-
style (commensal versus pathogenic).
The strong interaction ofC. jejuniwith chickenmucin suggests
that this is an important colonization factor for the organism.
Therefore, alteration of the glycosylation profile of the chicken
intestinal tract may be a viable means of decreasing the Campylo-
bacter burden in chickens in order to reduce the risk of transmis-
sion to humans. In support of this, previous studies have shown
that constituents of poultry feed alter mucin carbohydrates of the
chick intestinal tract and that these alterations result in reduced
numbers of C. jejuni bacteria colonizing the chicks (55).
Natural infection with H. pylori occurs only in humans and
nonhuman primates. Perhaps, therefore, it is not surprising that
the interactions between H. pylori and mucins from different an-
imals were not as strong as that between C. jejuni and chicken
mucin. It is of interest thatH. pylori bound best to mucin isolated
fromporcine stomachmucus, since the gnotobiotic piglet was one
of the first animal species to be experimentally infected with H.
pylori (56). The BabA adhesins of H. pylori strains J99 and G27
were demonstrated to interact with porcine stomach mucin.
However, strain 26695, though able to interact with porcine stom-
ach mucin, did not appear to have a functional BabA adhesin, as
assessed both by the mucin overlay blotting experiment and by
testing of direct binding to an NGC array. This finding is in agree-
ment with other studies (12). While the predicted protein se-
quences of the BabA adhesins are 	91% identical (using BLAST
algorithms from GenBank and the Institute for Genomic Re-
search, now the J. Craig Venter Institute) for all three strains, the
gene locations differ (11). In strainsG27 and J99, babA is located at
what is termed the babA locus, while in 26695, it is at a locus
normally associated with a BabA paralogue, BabB (11). Despite
the lack of a functional BabA protein, 26695 did not show a reduc-
tion in binding to mucins. This is in contrast to strain G27babA,
which had significantly lower levels of binding to mucins than the
wild-type strain G27. The BabA mutant was not complemented,
and therefore, the possibility that spontaneous mutation or phase
variation played a role in the reduction in binding cannot be ruled
out. Nevertheless, these findings suggest that while BabA is an
important H. pylori adhesin, other adhesin-glycan interactions
must also occur (as in the case of 26695) to fulfill a similar func-
tion. The binding of H. pylori to sialyl-Lewisx is mediated by the
OMP SabA (10). However, strain 26695 showed low binding to
sialyl-Lewisx on the NGC arrays. A previous study showed that
strain 26695 contains predominately out-of-frame sabA alleles
that do not express functional SabA protein (57). What adhesins
mediate the binding of strain 26695 to mucin has yet to be eluci-
dated.
We have shown previously that HT29-MTX-E12 cells can be
infected by both H. pylori and C. jejuni (20, 21). In this study, C.
jejuni infection was enhanced in, but not dependent on, the pres-
ence of mucus, whereas H. pylori required the presence of the
adherent mucus layer for effective infection. This suggests that
either themucus layer onHT29-MTX-E12 cells offered additional
H. pylori receptors not present on the other cell lines or themucus
induced an alteration in adhesins produced by the organism that
enabled interaction with the cells. Gastric mucins have been
shown to promote the proliferation of H. pylori and to alter gene
expression by the organism (58). Recently, we have shown that the
interaction of H. pylori with the trefoil peptide TFF1, present in
the adherent mucus layer of HT29-MTX E12 cells, promotes in-
fection (21). This finding highlights the role of nonmucin compo-
nents of mucus in mediating the colonization of mucosal surfaces
and warrants their further investigation.
FIG 8 Expression of Lewisb and sialyl-Lewisx by HT29-MTX-E12 cells. Im-
munofluorescence with specific antibodies was used to assess the expression of
the Lewisb or sialyl-Lewisx antigen by HT29-MTX-E12 cells grown for 21 days
on Transwell filters. DAPI staining was used to visualize cell nuclei. Arrow-
heads indicate staining of the extracellular mucus layer, and arrows indicate
cellular staining.
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While C. jejuni bound strongly to purified E12 mucin, we de-
tectedmarkedly reduced interaction ofH. pyloriwith E12mucins.
Structural analysis showed a paucity of fucosylated structures on
mucin fromHT29-MTX-E12 cells, despite the strong immunore-
activity of the adherent mucus layer with an antibody to Lewisb
blood group antigen. CsCl gradient fractionation suggested that
the Lewisb immunoreactive fractions colocated with glycolipids, a
finding corroborated by the detection of both Lewisb and sialyl-
Lewisx on purified glycolipids (Fig. 9). Moreover, both H. pylori
and C. jejuni could interact with these glycolipid fractions. These
findings emphasize the importance of considering mucus-bound
glycolipids as a reservoir of microbial receptors that can be ex-
ploited by mucosal pathogens.
In summary, this study highlights the role mucus can play in
promoting bacterial infection. It demonstrates that two closely
related organisms interact very differently with mucins from var-
ious sources, most likely reflecting the site-specific nature of gly-
cosylation. Further analysis of the glycans present in mucus may
lead to the identification of unique ligands for these interactions
and, subsequently, to the development of novel therapeutic or
prophylactic compounds to reduce the burden of infection.
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